Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Fujifilm Diosynth Biotechnologies to make the biotech's lead candidates
January 26, 2018
By: Tim Wright
Editor-in-Chief, Contract Pharma
Regenxbio, a clinical-stage biotech that offers gene therapies based on its proprietary NAV Technology Platform, has teamed up with Fujifilm Diosynth Biotechnologies for the manufacture of Regenxbio’s lead product candidates, including RGX-314 and RGX-501, which will support late-stage clinical development and early commercialization. This partnership builds on the foundation of Regenxbio’s internal manufacturing and process development capabilities. “We are excited to enter into this partnership with Fujifilm, which secures access to capacity and resources that will enable us to produce our lead product candidates at commercial scale using processes developed at Regenxbio,” said Curran Simpson, senior vice president of technical operations, Regenxbio. “By aligning our agreement with Fujifilm to our internal capabilities, we believe we will be well-positioned to meet the NAV AAV production requirements for our current lead product candidates through early commercialization, and to support new, emerging product candidates that may enter our pipeline.” Under the terms of the agreement with Fujifilm, Regenxbio gains guaranteed capacity for the supply of NAV AAV drug substance manufactured under current good manufacturing practice (cGMP) at large scale—up to 2,000L—for three years, with the option to extend the agreement for an additional three years. Fujifilm facilities are compliant with global regulatory standards in support of the initiation of worldwide clinical trials for any Regenxbio lead product candidate. “We look forward to strengthening our relationship with Regenxbio, a leader in the development of innovative gene therapy products providing hope for patients,” said Martin Meeson, president and chief operating officer, Fujifilm Diosynth Biotechnologies, USA. “With our strong track record of execution, and with facilities and systems that are suitable for late stage and commercial production, we are well positioned to support the manufacturing needs of Regenxbio as it continues to move multiple product candidates toward commercialization.” The agreement with Fujifilm does not limit Regenxbio’s flexibility to invest in its own cGMP manufacturing capabilities as clinical data emerge on lead product candidates. Regenxbio will continue to maintain existing relationships with contract manufacturing organizations for access to additional capacity, if so desired. Regenxbio continues to extend its manufacturing capabilities and intellectual property at its advanced manufacturing and analytics lab in Rockville, MD. Regenxbio has developed the ability to manufacture NAV AAV across multiple platforms from adherent-based processes to the scale-up of suspension-based systems, and now has the internal capability to produce NAV AAV at a scale of up to 200L.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !